YD BioMed expects to advance two lead ophthalmology programs utilizing its LSC Exosome platform, each supported by targeted regulatory and clinical milestones, which the timing of these milestones ...

BostonGene, the developer of an AI foundation model for tumor and immune biology, has entered a strategic collaboration with ...

Oruka Therapeutics, Inc. announced progress in its clinical programs with ORKA-001 and ORKA-002, targeting chronic skin diseases like psoriasis. The company completed dosing in a Phase 1 trial for ...

The collaboration leverages BostonGene's foundation model for tumor and immune biology to deliver predictive insights on patient-level safety and efficacy outcomes in early clinical trials.

The coronavirus pandemic prompted the speedy development of lifesaving Covid-19 vaccines, showcasing the pharmaceutical industry’s ability to deliver groundbreaking scientific innovations to the ...

The "In Silico Clinical Trials Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The in silico clinical trials market is undergoing rapid transformation, ...

In November 2025, the UK government introduced the national "Government Strategy and Roadmap" for phasing out animal testing.[1] The US Food and Drug Administration (FDA) has also issued a roadmap and ...

Science 37’s Operating System to enhance Worldwide Clinical Trials’ approach to decentralized clinical trials for faster enrollment, better retention, and more representative solutions RESEARCH ...

Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced that it has received the written meeting ...

Site augmentation emerges as a dynamic response to the growing complexity and volume of clinical trials, and the challenge of limited resources at clinical research sites. This support model, which is ...

Over the past few years, we’ve seen a wave of digital innovation in clinical trials: decentralized models, eConsent, real-time monitoring and direct-to-patient logistics. We’ve digitized nearly every ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...